Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Atherosclerosis AND control group

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Atherosclerosis AND control group. Displaying page 1 of 1.
    EudraCT Number: 2021-006295-17 Sponsor Protocol Number: MedTrace-002 Start Date*: 2022-04-08
    Sponsor Name:MedTrace Pharma
    Full Title: A Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered 15O- H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Con...
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10006896 CAD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001381-26 Sponsor Protocol Number: CER-001-CLIN-010 Start Date*: 2015-07-22
    Sponsor Name:CERENIS THERAPEUTICS SA
    Full Title: A PHASE II MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FOCUSING TRIAL OF CER-001 IN SUBJECTS WITH ACUTE CORONARY SYNDROME
    Medical condition: Acute Coronary Syndrome (ACS) with significant plaque volume
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001578-28 Sponsor Protocol Number: MeES/05/Neb-EnD/001 Start Date*: 2006-01-17
    Sponsor Name:Berlin-Chemie AG Menarini Group
    Full Title: Comparison the effects of Nebivolol versus Metoprolol succinate on endothelial function and large artery stiffness. A parallel group, randomized, double-blind, active control phase IV clinical tria...
    Medical condition: Atherosclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023801-36 Sponsor Protocol Number: RVX222-CS-007 Start Date*: 2011-09-26
    Sponsor Name:Resverlogix Corp.
    Full Title: Phase IIb multi-center, double-blind, randomized, parallel group, placebo-controlled clinical trial for the assessment of coronary plaque changes with RVX000222, as determined by intravascular ultr...
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004000-13 Sponsor Protocol Number: D356IC00001 Start Date*: 2008-02-07
    Sponsor Name:AstraZeneca AB
    Full Title: Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN (SATURN): A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comp...
    Medical condition: Coronary Atheroma -- The current trial will study patients who have a clinical indication for coronary catheterization and who have coronary artery disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) IT (Completed) BE (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005227-42 Sponsor Protocol Number: PM1108357 Start Date*: 2007-08-30
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A double-blind, placebo-controlled, parallel study to evaluate the effects of GW-856553 on endothelial function/ vascular compliance in subjects with dyslipidaemia.
    Medical condition: GW-856553 is under development as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002267-24 Sponsor Protocol Number: CRAD001A2413 Start Date*: 2005-07-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Assessment of everolimus in addition to calcineurin inhibitors reduction in maintenance renal transplant recipients (ASCERTAIN)
    Medical condition: Renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    M15 10023438
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) IT (Completed) ES (Completed) DK (Completed) CZ (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002607-17 Sponsor Protocol Number: TSX/01/C Start Date*: 2005-11-18
    Sponsor Name:Prostrakan Pharmaceuticals Ltd
    Full Title: Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus
    Medical condition: Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001556-20 Sponsor Protocol Number: SB-480848/026 Start Date*: 2005-11-01
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Integrated Biomarker and Imaging Study – 2 (IBIS-2)
    Medical condition: SB-480848 is under developement as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DE (Completed) AT (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-002518-11 Sponsor Protocol Number: 8835-004 Start Date*: 2014-01-16
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES ME...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) GB (Completed) IT (Completed) ES (Completed) BG (Completed) PL (Completed) GR (Completed) HR (Completed) SK (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-005033-22 Sponsor Protocol Number: UOL001362 Start Date*: 2019-06-19
    Sponsor Name:University of Liverpool
    Full Title: In patients taking Protease Inhibitors does switching to a Bictegravir, Tenofovir Alafenamide and Emtricitabine combination, reduce cardiovascular risk: An open-label, randomised, serial CT pilot s...
    Medical condition: Human immunodeficiency virus (HIV) and cardiovascular disease (CVD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10003581 Asymptomatic HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-002810-20 Sponsor Protocol Number: D356FC00003 Start Date*: 2007-09-13
    Sponsor Name:AstraZeneca AB
    Full Title: A 12-week Open-Label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to compare the Efficacy and Safety of rosuvastatin (CRESTOR) 10 mg and 20 mg in Combination with Ezetimibe 10 mg and ...
    Medical condition: Dyslipidemia - Expert groups have identified low-density lipoprotein cholesterol (LDL-C) as the primary target for cholesterol lowering therapy because it is strongly associated with coronary heart...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005532-18 Sponsor Protocol Number: PLX-CLI-03 Start Date*: 2017-01-02
    Sponsor Name:Pluristem Ltd.
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatmen...
    Medical condition: Critical Limb Ischemia (CLI)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10058069 Critical limb ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) AT (Completed) HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002508-13 Sponsor Protocol Number: PADHIF00704 Start Date*: 2005-04-13
    Sponsor Name:Genzyme Europe BV
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-Selection Study of Ad2/Hypoxia Inducible Factor HIF-1alfa/VP16 in Patients with Intermittent Claudication.
    Medical condition: Peripheral Arterial Disease (PAD): Intermittent Claudication (IC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009241 Claudication intermittent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000300-18 Sponsor Protocol Number: GN10DI406 Start Date*: 2011-09-08
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: REducing with MetfOrmin Vascular Adverse Lesions in T1DM (The REMOVAL study)
    Medical condition: People with type 1 diabetes with risk factors for cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 08:47:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA